ReciBioPharm and Acuitas Therapeutics will perform technology transfers and current good manufacturing practice (CGMP) manufacturing for customers licensing Acuitas’ lipid nanoparticle (LNP) formulations for mRNA-based therapeutics and vaccines.

ReciBioPharm first partnered with Acuitas Therapeutics in May of 2022 as Arranta Bio (now part of ReciBioPharm) and has since transferred and manufactured multiple Acuitas LNP formulations for planned clinical trials around the globe.

Ongoing work with Acuitas is being performed at ReciBioPharm’s U.S. Center of Excellence for Nucleic Acids, an 80,000 square foot facility in Watertown, MA., with 10,000 square feet of process development labs, 5,000 square feet of analytical labs and 13 cGMP production suites.

ReciBioPharm provides comprehensive nucleic acid services at its Watertown site, producing E. coli plasmid cell banks, CGMP plasmid DNA, multiple types of RNA drug substances, and LNP formulations with sterile fill-finish.

“This collaboration has enabled a number of Acuitas partners to rapidly progress from concept to clinic thanks to Acuitas’ deep process and analytical experience and our flexible development capability and strong CGMP execution,” said Nathaniel Youndt, vice president of business strategy and program management at ReciBioPharm. “We look forward to continuing our work together and, with Acuitas’ licensed customer base, to bringing new mRNA-based therapeutics to patients.”

“At Acuitas, we have a commitment to excellence and a high standard for quality control for our proprietary delivery technology and the ReciBioPharm team has the same dedication to the manufacturing and transfer of our LNP,” said Chris Barbosa, vice president of technology development. “We are proud to call them our partners and look forward to the continuation of this positive business relationship.”